


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS:


1-23. (cancelled)

24. (currently amended) A compound of the following general formula (I):






wherein R_1 and R_2 are fatty acyl groups selected from the group consisting of:



wherein m is 14 or 16 and n is an integer from 2 to 10.

25. (cancelled)

26. (currently amended) The compound according to claim 24, wherein R_1 and R_2 are selected from the group consisting of is palmitic acyl and R_2 is stearic acyl, and the compound having has the formula:




27. (previously presented) The compound according to claim 24, wherein at least one of R_1 and R_2 represents a hydroxyphthioceranoic acyl group.

28. (previously presented) The compound according to claim 24, wherein R_1 or R_2 represents a hydroxyphthioceranoic acyl group.

29. (currently amended) The compound according to claim 24, wherein:


- R_1 represents a hydroxyphthioceranoic acyl group, and R_2 represents a palmitic acyl group or a stearic acyl group, ~~namely compounds of~~ and the compound has the following formula (II):



[[III]] II

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, or


- R₂ represents a hydroxyphthioceranoic acyl group, and R₁ represents a palmitic acyl group or a stearic acyl group, ~~namely compounds of~~ and the compound has the following formula (III):



[[III]] III

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10.

30. (currently amended) The compound according to claim 24, wherein the compound is of the following formula II,



[[III]] II

wherein the compound is selected from the group consisting of:

- $n = 2, m = 14$ and $p = 14$ (II.1) ;
- $n = 2, m = 14$ and $p = 16$ (II.2) ;
- $n = 2, m = 16$ and $p = 14$ (II.3) ;
- $n = 2, m = 16$ and $p = 16$ (II.4) ;
- $n = 3, m = 14$ and $p = 14$ (II.5) ;
- $n = 3, m = 14$ and $p = 16$ (II.6) ;
- $n = 3, m = 16$ and $p = 14$ (II.7) ;
- $n = 3, m = 16$ and $p = 16$ (II.8) ;
- $n = 4, m = 14$ and $p = 14$ (II.9) ;
- $n = 4, m = 14$ and $p = 16$ (II.10) ;
- $n = 4, m = 16$ and $p = 14$ (II.11) ;
- $n = 4, m = 16$ and $p = 16$ (II.12) ;
- $n = 5, m = 14$ and $p = 14$ (II.13) ;
- $n = 5, m = 14$ and $p = 16$ (II.14) ;
- $n = 5, m = 16$ and $p = 14$ (II.15) ;
- $n = 5, m = 16$ and $p = 16$ (II.16) ;

- $n = 6, m = 14$ and $p = 14$ (II.17) ;
- $n = 6, m = 14$ and $p = 16$ (II.18) ;
- $n = 6, m = 16$ and $p = 14$ (II.19) ;
- $n = 6, m = 16$ and $p = 16$ (II.20) ;


- $n = 7, m = 14$ and $p = 14$ (II.21) ;
- $n = 7, m = 14$ and $p = 16$ (II.22) ;
- $n = 7, m = 16$ and $p = 14$ (II.23) ;
- $n = 7, m = 16$ and $p = 16$ (II.24) ;

- $n = 8, m = 14$ and $p = 14$ (II.25) ;
- $n = 8, m = 14$ and $p = 16$ (II.26) ;
- $n = 8, m = 16$ and $p = 14$ (II.27) ;
- $n = 8, m = 16$ and $p = 16$ (II.28) ;

- $n = 9, m = 14$ and $p = 14$ (II.29) ;
- $n = 9, m = 14$ and $p = 16$ (II.30) ;
- $n = 9, m = 16$ and $p = 14$ (II.31) ;
- $n = 9, m = 16$ and $p = 16$ (II.32) ;

- $n = 10, m = 14$ and $p = 14$ (II.33) ;
- $n = 10, m = 14$ and $p = 16$ (II.34) ;
- $n = 10, m = 16$ and $p = 14$ (II.35) ; and
- $n = 10, m = 16$ and $p = 16$ (II.36) ;

or of the following formula III,



[[III]] III

wherein the compound is selected from the group consisting of

- n = 2, m = 14 and p = 14 (III.1) ;
- n = 2, m = 14 and p = 16 (III.2) ;
- n = 2, m = 16 and p = 14 (III.3) ;
- n = 2, m = 16 and p = 16 (III.4) ;

- n = 3, m = 14 and p = 14 (III.5) ;
- n = 3, m = 14 and p = 16 (III.6) ;
- n = 3, m = 16 and p = 14 (III.7) ;
- n = 3, m = 16 and p = 16 (III.8) ;

- n = 4, m = 14 and p = 14 (III.9) ;
- n = 4, m = 14 and p = 16 (III.10) ;
- n = 4, m = 16 and p = 14 (III.11) ;
- n = 4, m = 16 and p = 16 (III.12) ;

- n = 5, m = 14 and p = 14 (III.13) ;
- n = 5, m = 14 and p = 16 (III.14) ;
- n = 5, m = 16 and p = 14 (III.15) ;
- n = 5, m = 16 and p = 16 (III.16) ;

- n = 6, m = 14 and p = 14 (III.17) ;
- n = 6, m = 14 and p = 16 (III.18) ;

- $n = 6, m = 16$ and $p = 14$ (III.19) ;
- $n = 6, m = 16$ and $p = 16$ (III.20) ;


- $n = 7, m = 14$ and $p = 14$ (III.21) ;
- $n = 7, m = 14$ and $p = 16$ (III.22) ;
- $n = 7, m = 16$ and $p = 14$ (III.23) ;
- $n = 7, m = 16$ and $p = 16$ (III.24) ;

- $n = 8, m = 14$ and $p = 14$ (III.25) ;
- $n = 8, m = 14$ and $p = 16$ (III.26) ;
- $n = 8, m = 16$ and $p = 14$ (III.27) ;
- $n = 8, m = 16$ and $p = 16$ (III.28) ;


- $n = 9, m = 14$ and $p = 14$ (III.29) ;
- $n = 9, m = 14$ and $p = 16$ (III.30) ;
- $n = 9, m = 16$ and $p = 14$ (III.31) ;
- $n = 9, m = 16$ and $p = 16$ (III.32) ;

- $n = 10, m = 14$ and $p = 14$ (III.33) ;
- $n = 10, m = 14$ and $p = 16$ (III.34) ;
- $n = 10, m = 16$ and $p = 14$ (III.35) ; and
- $n = 10, m = 16$ and $p = 16$ (III.36) .


31. (currently amended) ~~Compounds~~ The compound
according to claim 24, ~~of following formulae~~ having a formula
selected from the group consisting of:




[[III.21]] III.21,




[[II.21]] II.21,



[[III.2]] III.2,



[[III.23]] III.23, and




[[II.23]] II.23 .

32. (currently amended) A composition comprising a mixture of at least two different compounds of formula I ~~such as defined in~~ according to claim 24, wherein the at least two different compounds of formula (I) have different definitions for at least one of R_1 and R_2 .

33. (currently amended) ~~[[A]]~~ The composition according to claim 32, ~~characterized in that it comprises a~~ wherein the mixture ~~of compounds~~ of at least two different compounds is selected from [[the]]


(i) compounds ~~of following~~ according to formula (II):



[[I]] II

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, and the compounds differ by at least one of p, m or n or


(ii) ~~from the compounds of following~~ according to formula (III):




[[III]] III

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, and the compounds differ by at least one of p, m or n.


34. (currently amended) [[A]] The composition according to claim 32, ~~characterized in that it comprises a~~ wherein the mixture of compounds selected from at least two different compounds is the following compounds:




[[III.21]] III.21




[[II.21]] II.21




[[III.22]] III.22



[[III.22] II.22



[[III.23] III.23, and



[[II.23] II.23.

35. (currently amended) The composition according to claim 34, wherein the compounds represent from about 20% to about 100%, ~~more particularly about 30%,~~ of the total amount of compounds of formula I of said composition.

36. (previously presented) A pharmaceutical composition comprising at least one compound of claim 24, in association with a pharmaceutically acceptable vehicle.

37. (previously presented) The pharmaceutical composition according to claim 36, characterized in that it is presented in a form intended for administration by oral or injectable route.

38. (currently amended) [[A]] The pharmaceutical composition according to claim 36, ~~characterized in that it comprises~~ further comprising one or more other products useful for the treatment or the prophylaxis of tuberculosis, ~~such as BCG or mycobacterial proteins~~ selected from the group consisting of cytokines, DNA fragments encoding *M. tuberculosis* antigens, live *M. tuberculosis* deletion mutants and live recombinant Bacillus of Calmette and Gerinor.

39. (currently amended) A product comprising:
- at least one compound [[of]] according to claim 24,
- and at least one other product useful for the treatment or the prophylaxis of tuberculosis selected from the group consisting of cytokines, DNA fragments encoding *M. tuberculosis* antigens, live *M. tuberculosis* deletion mutants and live recombinant Bacillus of Calmette and Gerinor,

as a combined preparation for simultaneous, separate or sequential use in the treatment or the prophylaxis of tuberculosis.

40. (currently amended) A method for the treatment or the prophylaxis of tuberculosis, comprising the administration of

a therapeutically effective amount to a patient of at least one compound ~~[[of]]~~ according to claim 24.

41. (currently amended) A method of activating immune reaction, comprising the administration of a therapeutically effective amount to a patient of at least one compound~~[[of]]~~ according to claim 24.

42. (currently amended) A method of inducing the activation of T lymphocytes, comprising the administration of a therapeutically effective amount to a patient of at least one compound ~~[[of]]~~ according to claim 24.

43. (currently amended) A method of inducing the production of IFN- γ , TNF- α , IL-4 or granulysin, comprising the administration of a therapeutically effective amount to a patient of at least one compound ~~[[of]]~~ according to claim 24.

44-45. (cancelled)

46. (withdrawn-currently amended) A process for screening ~~products, such as sulfoglycolipids~~ for the compound according to claim 24 extracted from *Mycobacterium tuberculosis*, ~~characterised in that said process comprises~~ comprising the following stages:

- contacting dendritic cells loaded with the ~~product compound~~ compound to screen, notably sulfoglycolipids extracted from *Mycobacterium tuberculosis*, with T cell clones ~~according to claim 45, and~~
- detecting a molecule selected from the group comprising consisting of IFN- γ , TNF- α , granulysin and IL-4, released by the T cell clones,

wherein the T cell clones are generated by a process comprising the steps of:

- incubating antigen presenting cells (APCs) with a *Mycobacterium tuberculosis* envelope preparation substantially devoid of proteins, to obtain non-protein envelope antigen loaded APCs,
- contacting peripheral blood mononuclear cells with the envelope antigen loaded APCs to obtain proliferating T cells, and
- cloning proliferating T cells by limiting dilution and selecting the clones releasing a molecule selected from the group consisting of IFN- γ , TNF- α , granulysin and IL-4 when contacted by envelope antigen loaded APCs to obtain T cell clones.

47. (currently amended) A process for the extraction of ~~compounds~~ the compound of claim 24, from *Mycobacterium tuberculosis*, ~~characterized in that said process comprises~~ comprising the following stages:

- ~~treatment of~~ treating *M. tuberculosis* bacteria with a mixture of methanol and chloroform to obtain a chloroform/methanol extract,
- ~~concentration of~~ concentrating the chloroform/methanol extract followed by its partition between a chloroform phase and an aqueous phase,
- taking of the chloroform phase and evaporation of most of the chloroform, followed by ~~addition of~~ adding acetone thereto to obtain a precipitate and a soluble acetone phase,
- taking of the soluble acetone phase followed by concentration, and ~~application of~~ applying the concentrated soluble acetone phase on a silicic acid

column irrigated with mixtures of methanol and chloroform,

- ~~elution of~~ eluting a fraction from the above-mentioned silicic acid column by a mixture of chloroform and approximately 20% methanol,
- if necessary ~~purification of~~ purifying the fraction eluted from the silicic acid column to obtain different preparations respectively containing substantially only one compound.